IMV Inc (IMV):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7987)
◆英語タイトル:IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7987
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
IMV Inc (IMV), formerly Immunovaccine Inc, is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and infectious disease vaccines. The company’s product candidates include DPX-Survivac, a T cell activating immunotherapy that identifies and disrupts cancer biology in solid and hematological cancers; DPX-E7, an investigational immunotherapy that targets a viral protein in human papillomavirus in cervical and related cancers; and DPX-RSV, a lead infectious disease candidate is a small B cell epitope peptide vaccine intended to address the needs in respiratory syncytial virus. The company partners with various universities, research institutes and other vaccine development companies to develop its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.

IMV Inc (IMV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
Equity Offering 19
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 29
Immunovaccine Completes Private Placement Of Shares For US$4 Million 30
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 33
IMV Inc – Key Competitors 34
IMV Inc – Key Employees 35
IMV Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Strategy And Business Planning 37
Sep 04, 2018: IMV Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia 37
Financial Announcements 38
Aug 08, 2018: IMV announces Q2 2018 financial results 38
May 14, 2018: IMV Announces Q1 2018 Financial Results 40
Mar 20, 2018: Immunovaccine Announces Year-End 2017 Financial Results 42
Nov 09, 2017: Immunovaccine Announces Third Quarter 2017 Financial Results 44
Aug 08, 2017: Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017 45
May 10, 2017: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017 47
Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 48
Corporate Communications 51
Jun 07, 2018: IMV Appoints Julia P. Gregory to Board of Directors 51
May 31, 2018: Nasdaq Approves Listing of IMV Common Shares 52
Jan 18, 2018: Immunovaccine Appoints Joseph Sullivan as Senior Vice President of Business Development 53
Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 54
Product News 55
Jan 31, 2018: Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression 55
Clinical Trials 56
Oct 05, 2017: Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Companys DepoVax-based Programs 56
Apr 12, 2017: Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate 57
Other Significant Developments 58
May 10, 2018: IMV – Change of ticker on OTCQX from IMMVF to IMMVD 58
Aug 08, 2017: Immunovaccine Issues Second Quarter 2017 Letter to Shareholders 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
IMV Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 29
Immunovaccine Completes Private Placement Of Shares For US$4 Million 30
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 33
IMV Inc, Key Competitors 34
IMV Inc, Key Employees 35
IMV Inc, Other Locations 36

List of Figures
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ IMV Inc (IMV):製薬・医療:M&Aディール及び事業提携情報(IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆